Survey Snippets #5: Three Tips To Successfully Scale Your Transformation Business Case
Industrial companies today face many challenges, building business cases doesn't need to be one of them. Learn how to successfully scale your...
TOPIC
Industry 4.0 / Smart Manufacturing (2)
Filter by:
What is Quality 4.0? And What It Isn’t.
LNS Research's Vivek Murugesan answers key questions regarding the scope and value of Quality 4.0 and its role within Industrial Transformation (IX).
Blast From the Past: Industrial Transformation Lessons From the 15th Century
Travel back in time to the Renaissance movement in 15th century Florence, Italy and learn lessons manufacturers can apply to get ahead in their IX...
The IX Journey: Five Stages of Industrial Transformation (IX)
Explore the five stages of IX maturity and learn why LNS Research believes the Transformation Chasm is the single biggest challenge to IX success.
My Biggest 2022 Prediction: Guess What Gets A Reset...Again
Check out what prediction– in multiple parts - LNS Research Principal Analyst Tom Comstock is going to make surrounding Industrial Transformation in...
Seven Key Take-Aways from the Sustainability and EHS Leaders Roundtable
Peter Bussey highlights seven key take-aways from The IX Events roundtable session on Sustainability and EHS that can help guide Sustainability...
Evaluating Potential Industrial Transformation (IX) Strategic Partners
Revisit our definition of IX Strategic Partners, the criteria used to evaluate vendors, and the list of vendors as we ready our next Solution...
The M&A Rumble in the Jungle
Catch up on the recent M&A announcements, LNS Research's view of where the industry is heading, and our predictions for 2021 with Principal Analyst,...
Operational Risk Management Gets Smart with AI
Learn how Operational Risk Management is becoming more intelligent through Real World AI and Machine Learning Solutions with LNS Research's Peter...
Should Pharma Regain MES Leadership or Become the New IX Leaders?
Principal Analyst, Andrew Hughes, discusses the choice pharma companies need to make: regain their leadership in MES or become the new leaders in IX